TriReme Medical announced in a company release that the first three patients were enrolled in a clinical study of its unique drug-coated Chocolate percutaneous transluminal angioplasty balloon. Andrew Holden, co-principal investigator of the study, performed these procedures at Auckland City Hospital, in Auckland, New Zealand.
Metactive Medical presented new nonclinical data on one of its investigational devices at the Society of Interventional Radiology’s (SIR) Annual Scientific Meeting. The presentation focused on the company’s device that addresses the cerebral aneurysm market
A study, published in the Journal of Vascular and Interventional Radiology, highlights the benefits of the transradial approach to treat uterine fibroids and investigators find that this technique could be a “game changer” for image-guided minimally invasive treatments.
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling.
Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer.
The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA)
March 29, 2014—AccessClosure Inc. (Santa Clara, CA) announced the commercial launch of its Mynx Ace vascular closure device at ACC.14: the 63rd annual scientific session of the American College of Cardiology being held March 29–31, in Washington, DC.
March 30, 2014—Medtronic, Inc. (Minneapolis, MN) announced to the presentation of an analysis of 6-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry. The data were presented during a late-breaking clinical trial session at ACC.14, the 63rd scientific sessions of the American College of Cardiology (ACC) in Washington, DC.
March 29, 2014—Medtronic, Inc. (Minneapolis, MN) announced that the full results of the SYMPLICITY HTN-3 clinical trial were presented in a late-breaking session at the ACC.14: 63rd annual scientific sessions of the American College of Cardiology and published simultaneously online ahead of print in The New England Journal of Medicine. SYMPLICITY HTN-3 is a blinded, randomized, sham-controlled study of renal denervation for treatment-resistant hypertension. ACC.14 is being held on March 29–31, in Washington, DC.
March 24, 2014—The Society of Interventional Radiology (SIR) announced findings from a study demonstrating that 72% of men with benign prostatic hyperplasia who were treated via prostate artery embolization (PAE) continued to show symptom improvement at 3-year follow-up. Minimally invasive, image-guided PAE is a transcatheter procedure that releases microscopic beads into the artery where they lodge and temporarily block blood flow to the prostate, causing it to shrink. The study was presented at SIR’s 39th Annual Scientific Meeting in San Diego, California, and is available online as Abstract 108 at www.sirmeeting.org.
March 24, 2014—The Society of Interventional Radiology (SIR) announced that yttrium-90 (Y-90) radioembolization of the artery that supplies the liver shows promise in treating breast cancer that has spread to the liver when no other treatment options remain. In this procedure, microbeads are administered into the blood stream, float out to the smaller vessels that feed the tumor, and emit cancer-killing radiation from inside the tumor. Because Y-90 is targeted directly to the tumor, radiation damage to healthy surrounding tissues is minimized. The study was presented at the SIR’s 39th annual scientific meeting in San Diego, California, and is available as Abstract 192 at www.sirmeeting.org.
April 7, 2014—Alvimedica Medical Technologies (Catalca, Turkey) announced the launch of the Cre8 BTK drug-eluting stent (DES), a polymer-free device for the treatment of below-the-knee (BTK) lesions, as part of the company s introduction of its endovascular device portfolio. The device was launched at the Charing Cross international symposium in London, United Kingdom, for use in the European Union and other markets that recognize CE Mark approval, which the company received in July 2013.
April 5, 2014—Twelve-month results from the IN.PACT SFA trial studying the In.Pact Admiral drug-coated balloon (DCB) (Medtronic, Inc., Minneapolis, MN) were presented at the Charing Cross international symposium in London. Principal investigator Gunnar Tepe, MD, presented the data, which showed that patients with peripheral artery disease in the superficial femoral artery (SFA) who were treated with the In.Pact Admiral device experienced significantly better outcomes at 12 months after treatment compared to those treated with standard percutaneous transluminal angioplasty (PTA).
March 27, 2014—CryoLife, Inc. (Kennesaw, GA) announced that it has acquired the exclusive worldwide distribution rights for the ProCol vascular bioprosthesis from Hancock Jaffe Laboratories, Inc. (Irvine, CA), and it has the right to acquire the ProCol product line from Hancock Jaffe, beginning 24 months after execution of the agreement.
BioCardia announced receipt of the CE mark for its Morph AccessPro steerable introducer, designed for easier navigation through the vasculature during delivery of biotherapeutics and medical devices.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos